Company profile
SEC EDGAR ↗- Industry
- Pharmaceutical Preparations
- Listed
- NYSE: AZN
- Incorporated
- United Kingdom
- Headquarters
- Cambridge
- Fiscal year end
- Dec 31
Financials
FY2025- Revenue
- $58.7B
- Net income
- $10.2B
- Total assets
- $114.1B
| Fiscal year | Revenue | Net income | Total assets |
|---|---|---|---|
| FY2025 | $58.7B | $10.2B | $114.1B |
| FY2024 | $54.1B | $7.04B | $104.0B |
| FY2023 | $45.8B | $5.96B | $101.1B |
| FY2022 | $44.4B | $3.29B | $96.5B |
| FY2021 | $37.4B | $115.0M | $105.4B |
| FY2020 | $26.6B | $3.14B | $66.7B |
Reported fiscal years from SEC filings (20-F) — SEC EDGAR ↗. Stratrix is a strategy publication, not a real-time financial data service.
Decisions on record
One verified Decision Record on AstraZeneca, and the casebook each one belongs to.
| Fork date | Decision type | What AstraZeneca chose | Where it stood | The story | Casebook |
|---|---|---|---|---|---|
| 2014 | The Turnaround | Reject and stay independent | Total Revenue of $54.1 billion in 2024, up 18% (2024) | Read the story → | The Turnaround Casebook → |
Run one of these yourself
The decisions AstraZeneca faced, as kits you can run.
Each pack takes one of these decisions and gives you the framework, a deck for the room, a model that resolves to one number, and the sourced cases behind it. $499, one-time.
The analyses
The Market Entry Gambit · Growth & Portfolio
AstraZeneca's China Bet Got So Big It Can't Be Unwound — Even by a Scandal.
Police detained AstraZeneca's most senior international executive in November 2024. China still grew 11% to $6.4bn that year, and fourteen months later — during UK Prime Minister Starmer's state visit to Beijing from 28–31 January 2026 — the company pledged $15bn through 2030. The crisis isn't the story. The fact that none of it changes the bet is.
8 min
The Turnaround · Crisis & Reinvention
AstraZeneca Said No to £55 a Share on a Pipeline That Didn't Exist Yet
In 2014 AstraZeneca rejected Pfizer's final £55-a-share proposal, valuing it near £69.4 billion. The board called it too cheap. A decade later, $54.1 billion in 2024 revenue made them right - but they were betting on an oncology business that was barely born.
8 min